Differentiating Hodgkin Lymphoma and Sarcoid Reaction in Subsequent FDG-PET/CT: A Case Report and Literature Review.

IF 0.6 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING World Journal of Nuclear Medicine Pub Date : 2023-12-26 eCollection Date: 2023-12-01 DOI:10.1055/s-0043-1777694

Obayda Rabei, Ula Al-Rasheed, Mohammed Alrammahi, Akram Al-Ibraheem

{"title":"Differentiating Hodgkin Lymphoma and Sarcoid Reaction in Subsequent FDG-PET/CT: A Case Report and Literature Review.","authors":"Obayda Rabei, Ula Al-Rasheed, Mohammed Alrammahi, Akram Al-Ibraheem","doi":"10.1055/s-0043-1777694","DOIUrl":null,"url":null,"abstract":"<p><p>Sarcoidosis is frequently associated with various hematological and solid tumors; it can be discovered by chance during tumor evaluations. Sarcoidosis can occur before some cancers, coexist with others, or be diagnosed 1 to 2 years later. Sarcoid reaction affecting hilar and mediastinal lymph nodes can pose a diagnostic challenge in patients with histopathological confirmation of Hodgkin lymphoma who are being evaluated using fluorodeoxyglucose-positron emission tomography computed tomography (FDG-PET/CT) scan because it cannot be easily distinguished from lymphoma infiltration. The presence of an increase or persistence of a prominent activity on a follow-up FDG-PET/CT scan after chemotherapy treatment for lymphoma that is associated with a complete metabolic response in the site of the primarily diagnosed lymphomatous disease is highly suggestive of concurrent sarcoidosis and necessitates careful assessment to avoid unnecessary therapy.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751130/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0043-1777694","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Sarcoidosis is frequently associated with various hematological and solid tumors; it can be discovered by chance during tumor evaluations. Sarcoidosis can occur before some cancers, coexist with others, or be diagnosed 1 to 2 years later. Sarcoid reaction affecting hilar and mediastinal lymph nodes can pose a diagnostic challenge in patients with histopathological confirmation of Hodgkin lymphoma who are being evaluated using fluorodeoxyglucose-positron emission tomography computed tomography (FDG-PET/CT) scan because it cannot be easily distinguished from lymphoma infiltration. The presence of an increase or persistence of a prominent activity on a follow-up FDG-PET/CT scan after chemotherapy treatment for lymphoma that is associated with a complete metabolic response in the site of the primarily diagnosed lymphomatous disease is highly suggestive of concurrent sarcoidosis and necessitates careful assessment to avoid unnecessary therapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在随后的 FDG-PET/CT 中鉴别霍奇金淋巴瘤和肉芽肿反应：病例报告和文献综述。

肉样瘤病经常与各种血液肿瘤和实体瘤相关；它可能在肿瘤评估时偶然被发现。肉样瘤病可能发生在某些癌症之前，也可能与其他癌症并存，或在 1 到 2 年后才被诊断出来。对于组织病理学确诊为霍奇金淋巴瘤并正在接受氟脱氧葡萄糖-正电子发射计算机断层扫描（FDG-PET/CT）评估的患者来说，影响肺门淋巴结和纵隔淋巴结的肉样瘤反应会给诊断带来挑战，因为肉样瘤反应不易与淋巴瘤浸润区分开来。如果淋巴瘤化疗后的随访 FDG-PET/CT 扫描中出现明显的活动性增加或持续存在，且与主要确诊淋巴瘤疾病部位的完全代谢反应相关联，则高度提示并发肉样瘤病，有必要进行仔细评估，以避免不必要的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊